ConductScience.org, home

Paper17876013

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

Saltz LB and 11 others. J Clin Oncol, 2007. Cited by 371 papers, by iCite.

Cite this record

ConductScience Library. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. Papers, record 17876013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17876013

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
PubMed
Journal
J Clin Oncol
PubMed
Year
2007
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
371
iCite
Relative citation ratio, by iCite
7.87
iCite
Revised in PubMed
2022-02-25
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Saltz LBLeonard B
2Lenz HJHeinz-Josef
3Kindler HLHedy L
4Hochster HSHoward S
5Wadler SScott
6Hoff PMPaulo M
7Kemeny NENancy E
8Hollywood EMEllen M
9Gonen MMithat
10Quinones MMarcus
11Morse MMeroe
12Chen HXHelen X

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
CamptothecinMajor topic
Colorectal NeoplasmsMajor topic
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Bevacizumab
Cetuximab
Disease Progression
Female
Humans
Irinotecan
Male
Middle Aged
Neoplasm Metastasis
Treatment Outcome

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
N01-CM-07003-CM74SNCI NIH HHSUnited StatesPubMed
N01-CM-17003NCI NIH HHSUnited StatesPubMed
N01-CM-17102NCI NIH HHSUnited StatesPubMed
N01-CM17101NCI NIH HHSUnited StatesPubMed
N01-CM17105NCI NIH HHSUnited StatesPubMed

Source PubMed

Download CSV of grants

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in17876011Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet.https://conductscience.org/library/papers/17876011PubMed
Comment in18202430Bevacizumab: one treatment for all the seasons?https://conductscience.org/library/papers/18202430PubMed

Download CSV of comments and corrections

Cited by164

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 371 citations.

PMIDTitleJournalYearIn PapersSource
42321955Studying When to Add Biological Therapy to Cytotoxic Therapy in Advanced Cancer Care Using Real World Data: How to Avoid Design Choices That Generate Immortal Time.Cancer Med2026https://conductscience.org/library/papers/42321955PubMed
41974756A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer.Sci Rep2026https://conductscience.org/library/papers/41974756PubMed
41456238Immunohistochemical evaluation of EGFR protein expression and microvascular density reveals an angiogenic signature in Tunisian patients with metastatic colorectal cancer.Clin Transl Oncol2026https://conductscience.org/library/papers/41456238PubMed
40940901Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance.Cancers (Basel)2025https://conductscience.org/library/papers/40940901PubMed
38944037Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy.Cell Rep Med2024https://conductscience.org/library/papers/38944037PubMed
38811554Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients.NPJ Genom Med2024https://conductscience.org/library/papers/38811554PubMed
38775718
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).
J Natl Cancer Inst2024https://conductscience.org/library/papers/38775718PubMed
38254903Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer.Cancers (Basel)2024https://conductscience.org/library/papers/38254903PubMed
37456800KRAS mutations and their associations with clinicopathological features and survival in Vietnamese non‑polyp colon cancer patients.Mol Clin Oncol2023https://conductscience.org/library/papers/37456800PubMed
37409250Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements.Front Oncol2023https://conductscience.org/library/papers/37409250PubMed
36915460Using a combination of fruquintinib, raltitrexed, and S-1 as a third-line treatment for metastatic colorectal cancer with co-existence of Hodgkin lymphoma: a case report.J Gastrointest Oncol2023https://conductscience.org/library/papers/36915460PubMed
36578083KPNA2 promotes angiogenesis by regulating STAT3 phosphorylation.J Transl Med2022https://conductscience.org/library/papers/36578083PubMed
35380713Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.Oncologist2022https://conductscience.org/library/papers/35380713PubMed
35261903Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review.Transl Cancer Res2022https://conductscience.org/library/papers/35261903PubMed
35223449Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials.Front Oncol2021https://conductscience.org/library/papers/35223449PubMed
34712608Knockdown of PPARδ Induces VEGFA-Mediated Angiogenesis via Interaction With ERO1A in Human Colorectal Cancer.Front Oncol2021https://conductscience.org/library/papers/34712608PubMed
34476218Vascular Normalization: A New Window Opened for Cancer Therapies.Front Oncol2021https://conductscience.org/library/papers/34476218PubMed
34446980Monitoring cancer cell surface receptor expression during anti-angiogenesis therapy in vivo.Proc SPIE Int Soc Opt Eng2021https://conductscience.org/library/papers/34446980PubMed
34109130Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review.Front Oncol2021https://conductscience.org/library/papers/34109130PubMed
33868486Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer.Oncol Lett2021https://conductscience.org/library/papers/33868486PubMed

See all 164 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17876013

GET https://conductscience.org/api/papers/v1/17876013/cited_by?page=2